Drug intelligence / Profile preview

MG-GTX13

Development stage: Preclinical
Lead developer: MEPSGEN
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

MG-GTX13 is a nanomedicine candidate developed by MEPSGEN for the treatment of glioblastoma (GBM) and other brain tumors. It is part of the company's MG-X_Nanomedicine pipeline, which utilizes a proprietary biomimetic nanoparticle platform and microvortex synthesis technology (NanoCalibur™) to deliver therapeutic payloads across the blood-brain barrier (BBB). MG-GTX13 is designed to achieve targeted accumulation in brain tumor tissues through receptor-mediated endocytosis, potentially improving the efficacy and safety of treatment for aggressive central nervous system malignancies. The drug is currently in the preclinical stage of development.

Other names: MG-GTX13-MEPSGEN-nanomedicineMG-GTX-13-MEPSGEN-nanomedicineMG-GTX 13-MEPSGEN-nanomedicine

Beyond the preview

Go deeper on MG-GTX13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG-GTX13.

Explore the full profile